Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Reduction of adverse effects by a mushroom product, active hexose correlated compound (AHCC) in patients with advanced cancer during chemotherapy--the significance of the levels of HHV-6 DNA in saliva as a surrogate biomarker during chemotherapy.

Ito T, Urushima H, Sakaue M, Yukawa S, Honda H, Hirai K, Igura T, Hayashi N, Maeda K, Kitagawa T, Kondo K.

Nutr Cancer. 2014;66(3):377-82. doi: 10.1080/01635581.2014.884232. Epub 2014 Mar 10.

PMID:
24611562
2.

The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice.

Hirose A, Sato E, Fujii H, Sun B, Nishioka H, Aruoma OI.

Toxicol Appl Pharmacol. 2007 Jul 15;222(2):152-8. Epub 2007 Apr 20.

PMID:
17555784
3.

Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.

Yanagimoto H, Satoi S, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, Ryota H, Michiura T, Inoue K, Matsui Y, Tsuta K, Kon M.

Nutr Cancer. 2016;68(2):234-40. doi: 10.1080/01635581.2016.1134597. Epub 2016 Feb 4.

PMID:
26847832
5.

Effect of active hexose-correlated compound in women receiving adjuvant chemotherapy for breast cancer: a retrospective study.

Hangai S, Iwase S, Kawaguchi T, Kogure Y, Miyaji T, Matsunaga T, Nagumo Y, Yamaguchi T.

J Altern Complement Med. 2013 Nov;19(11):905-10. doi: 10.1089/acm.2012.0914. Epub 2013 Jul 5.

6.

Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.

Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W, Villa E, Verusio C, Cetto GL, Santo A, De Pangher V, Artioli F, Cacciani GC, Parodi G, Soresi F, Ghi MG, Morabito A, Biason R, Giusto M, Mosconi P, Chiarion Sileni V; GSTVP (Gruppo di Studio Tumori Polmonari del Veneto).

Lung Cancer. 2004 Jan;43(1):83-91.

PMID:
14698542
7.

Alleviating effect of active hexose correlated compound (AHCC) for anticancer drug-induced side effects in non-tumor-bearing mice.

Shigama K, Nakaya A, Wakame K, Nishioka H, Fujii H.

J Exp Ther Oncol. 2009;8(1):43-51.

PMID:
19827270
8.

[Chronic fatigue syndrome and herpesvirus reactivation].

Kondo K.

Nihon Rinsho. 2007 Jun;65(6):1043-8. Review. Japanese.

PMID:
17561695
9.

Prognostic improvement of patients with advanced liver cancer after active hexose correlated compound (AHCC) treatment.

Cowawintaweewat S, Manoromana S, Sriplung H, Khuhaprema T, Tongtawe P, Tapchaisri P, Chaicumpa W.

Asian Pac J Allergy Immunol. 2006 Mar;24(1):33-45.

10.

Health-related quality of life in early breast cancer.

Groenvold M.

Dan Med Bull. 2010 Sep;57(9):B4184.

PMID:
20816024
11.

Presence of Epstein-Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: associations with disease activity.

Höllsberg P, Kusk M, Bech E, Hansen HJ, Jakobsen J, Haahr S.

Acta Neurol Scand. 2005 Dec;112(6):395-402.

PMID:
16281923
12.

Evaluation of EORTC QLQ-C30 questionnaire in patients undergoing in-hospital chemotherapy for gastrointestinal cancer in Japan.

Kato J, Nagahara A, Iijima K, Yoshimura M, Osada T, Yoshizawa T, Watanabe S.

J Gastroenterol Hepatol. 2008 Dec;23 Suppl 2:S268-72. doi: 10.1111/j.1440-1746.2008.05414.x.

PMID:
19120910
13.

Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study.

Hiura Y, Takiguchi S, Yamamoto K, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Miyata H, Fujiwara Y, Mori M, Kangawa K, Doki Y.

Cancer. 2012 Oct 1;118(19):4785-94. doi: 10.1002/cncr.27430. Epub 2012 Jan 26.

14.

Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.

Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L, Van Cutsem E; V-325 Study Group.

J Clin Oncol. 2007 Aug 1;25(22):3210-6.

PMID:
17664468
15.

The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer.

Carey MS, Bacon M, Tu D, Butler L, Bezjak A, Stuart GC.

Gynecol Oncol. 2008 Jan;108(1):100-5. Epub 2007 Oct 24.

PMID:
17920108
16.

Assessing quality of life on the day of chemotherapy administration underestimates patients' true symptom burden.

Giesinger JM, Wintner LM, Zabernigg A, Gamper EM, Oberguggenberger AS, Sztankay MJ, Kemmler G, Holzner B.

BMC Cancer. 2014 Oct 10;14:758. doi: 10.1186/1471-2407-14-758.

17.

Quality of life in ovarian cancer patients receiving chemotherapy.

Lakusta CM, Atkinson MJ, Robinson JW, Nation J, Taenzer PA, Campo MG.

Gynecol Oncol. 2001 Jun;81(3):490-5.

PMID:
11371144
18.

Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.

Han K, Cummings BJ, Lindsay P, Skliarenko J, Craig T, Le LW, Brierley J, Wong R, Dinniwell R, Bayley AJ, Dawson LA, Ringash J, Krzyzanowska MK, Moore MJ, Chen EX, Easson AM, Kassam Z, Cho C, Kim J.

Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):587-94. doi: 10.1016/j.ijrobp.2014.06.061. Epub 2014 Sep 3.

PMID:
25194664
19.

Monitoring of human herpesvirus-6 and -7 genomes in saliva samples of healthy adults by competitive quantitative PCR.

Fujiwara N, Namba H, Ohuchi R, Isomura H, Uno F, Yoshida M, Nii S, Yamada M.

J Med Virol. 2000 Jun;61(2):208-13.

PMID:
10797376
20.

Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer.

Brown J, Thorpe H, Napp V, Fairlamb DJ, Gower NH, Milroy R, Parmar MK, Rudd RM, Spiro SG, Stephens RJ, Waller D, West P, Peake MD.

J Clin Oncol. 2005 Oct 20;23(30):7417-27. Epub 2005 Sep 12.

PMID:
16157935

Supplemental Content

Support Center